Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 2, 2011

Premium

Cepheid this week announced that Michael Bates has joined the company as vice president of oncology research and development.

Bates most recently was vice president of clinical research at Monogram Biosciences, which was acquired by LabCorp in 2009. Prior to that, he held positions at ViroLogic and Roche Laboratories.

At Cepheid, Bates will be responsible for the company's micro-RNA program and for the development and preclinical evaluation of Cepheid's targeted oncology portfolio, including the Xpert BCR-ABL test under development with Novartis; as well as Xpert tests for bladder and lung cancer.


Dennis Harris has been appointed as chief scientific officer at IntegenX, the company said this week.

Harris is a co-founder of IntegenX and has served on the company's board of directors since 2003. He served as CSO of Millipore until December 2010, when the company was acquired by Merck KGaA. Prior to that, he was vice president and CSO at Serologicals, which Millipore acquired in 2006. Harris has also worked at Amersham International and Amersham Pharmacia Biotech, now part of GE; and Aclara Biosciences.

Based in Pleasanton, Calif., IntegenX makes automated genomic sample preparation systems for the life sciences, applied sciences, and diagnostics markets.


Timothy Triche has joined WaferGen Biosystems' board of directors, the company said this week.

Triche, a professor of pathology and pediatrics at the University of Southern California Keck School of Medicine, is also a member of WaferGen's scientific advisory board, which he joined in December. Triche is also director of the Center for Personalized Medicine at Children's Hospital Los Angeles, where he previously also served as chief of pathology and laboratory medicine for more than 20 years. Prior to that, Triche was section chief and head of molecular diagnostics in the laboratory of pathology at the National Cancer Institute.


Diffinity Genomics said this week that it has appointed John Foskett and Robert Evans to its board of directors.

Foskett is the co-founder and technical director of Kapa Biosystems. He has joined Diffinity's board as the representative of Table Mountain Capital, a private investment company where he serves as founding partner and investment committee member. Foskett is also a partner with LH Investments.

Evans is currently a management consultant providing services in general management, sales and marketing, acquisitions, and divestitures involving medical device manufacturers. He has previously served as corporate vice president of Graphic Controls. Prior to that, he served as general manager of Abbott Laboratories' Medlon Products Division; general manager of Abbott Ireland; and business unit manager of Abbott's Fluid Systems Division. Evans has joined Diffinity's board as the representative of a group of Series A shareholders that include the Rochester Angel Network, Seed Capital Fund of Central New York, and Western New York Venture Association.

Evans will replace Richard Richmond on Diffinity's board. Richmond has stepped down to devote more time to SimPore, where he serves as chairman.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.